Table 4.
Dataset | Main effect | Interaction | Multiple comparisons | |||||
---|---|---|---|---|---|---|---|---|
F (DFn,DFd) | p-value | F (DFn,DFd) | p-value | Effect | Groups | p-value | ||
Males OCR AUC | Treatment: F (1, 11) = 11.85 | 0.0055 | F (1, 11) = 5.817 | 0.0345 | Treatment | Vehicle | 0.5347 | |
Paclitaxel | 0.2303 | |||||||
Genotype: F (1, 11) = 0.1714 | 0.6868 | Genotype | WT | 0.0136 | ||||
eIF4ES209A | 0.8475 | |||||||
Females OCR AUC | Treatment: F (1, 17) = 6.074 | 0.0247 | F (1, 17) = 5.158 | 0.0364 | Treatment | Vehicle | 0.7519 | |
Paclitaxel | 0.1426 | |||||||
Genotype: F (1, 17) = 0.6271 | 0.4393 | Genotype | WT | 0.0455 | ||||
eIF4ES209A | 0.9982 | |||||||
Males ECAR AUC | Treatment: F (1, 11) = 13.04 | 0.0041 | F (1, 11) = 16.26 | 0.0020 | Treatment | Vehicle | 0.1313 | |
Paclitaxel | 0.0303 | |||||||
Genotype: F (1, 11) = 0.2927 | 0.5993 | Genotype | WT | 0.0021 | ||||
eIF4ES209A | 0.9866 | |||||||
Females ECAR AUC | Treatment: F (1, 17) = 7.989 | 0.0116 | F (1, 17) = 2.068 | 0.1686 | Treatment | Vehicle | 0.6269 | |
Paclitaxel | 0.8523 | |||||||
Genotype: F (1, 17) = 0.1287 | 0.7242 | Genotype | WT | 0.0792 | ||||
eIF4ES209A | 0.6287 | |||||||
Breakdown datasets for OCR | Interaction | p-value | Multiple comparisons - groups compared | p-value | ||||
Males basal respiration | F (3, 8) = 233.2 | <0.0001 | WT vehicle | WT paclitaxel | <0.0001 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.0134 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.0018 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | <0.0001 | ||||||
Females basal respiration | F (3, 8) = 838.7 | <0.0001 | WT vehicle | WT paclitaxel | <0.0001 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | <0.0001 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.8413 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | <0.0001 | ||||||
Males ATP turnover | F (3, 12) = 2.384 | 0.1203 | WT vehicle | WT paclitaxel | 0.0905 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.9832 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.9188 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.5864 | ||||||
Females ATP turnover | F (3, 12) = 8.828 | 0.0023 | WT vehicle | WT paclitaxel | 0.0021 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.6736 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.9766 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.0481 | ||||||
Males maximal respiration | F (3, 28) = 2.233 | 0.1064 | WT vehicle | WT paclitaxel | 0.0661 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.9857 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.8539 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.6683 | ||||||
Females maximal respiration | F (3, 28) = 5.986 | 0.0028 | WT vehicle | WT paclitaxel | 0.0011 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | >0.9999 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.4836 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.0417 | ||||||
Males non-mitochondrial respiration (reserve capacity) | F (3, 8) = 42.18 | <0.0001 | WT vehicle | WT paclitaxel | <0.0001 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.9978 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.0063 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.0010 | ||||||
Females non-mitochondrial respiration (reserve capacity) | F (3, 8) = 46.31 | <0.0001 | WT vehicle | WT paclitaxel | <0.0001 | |||
eIF4ES209A vehicle | eIF4ES209A paclitaxel | 0.0074 | ||||||
WT vehicle | eIF4ES209A vehicle | 0.0037 | ||||||
WT paclitaxel | eIF4ES209A paclitaxel | 0.9212 |
Two-way ANOVA was performed on AUC values for OCR and ECAR followed by Tukey’s post-hoc for multiple comparisons between genotypes and treatments for each sex. For breakdown data of mitochondrial respiration, ordinary one-way ANOVAs were used to analyze mean values of four groups (WT vehicle, WT paclitaxel, eIF4ES209A vehicle, and eIF4ES209A paclitaxel), followed by Sidak’s post-hoc for multiple comparisons between genotypes and treatments for each sex. p ≤ 0.05 was considered significant (bolded). OCR, oxygen consumption rate; ECAR, extracellular acidification rate.